| REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men (NCT04838769) | Boston Scientific Corporation | 2021-09-15 |
| HoLEP in Management of BPH Patients With Predominant Voiding vs Storage LUTS: A Comparative Retrospective Study (NCT04178811) | Assiut University | 2021-08-01 |
| To Evaluate the Feasibility, Preliminary Safety and Performance of Rezūm System in BPH Treatment in China (NCT04823221) | Boston Scientific Corporation | 2021-07-10 |
| Evaluation of Silodosin and Pelvic Floor Muscle Training in Men With Benign Prostatic Hyperplasia and Overactive Bladder (NCT04681625) | Comenius University | 2021-01-11 |
| Aquablation vs. Holmium Laser Enucleation of the Prostate in the Treatment of Benign Prostatic Hyperplasia in Medium to Large Size Prostates (NCT04560907) | Dr. med. Gautier Müllhaupt | 2021-01-05 |
| A Multi-center, International Prospective Follow up Study (NCT04579913) | Medi-Tate Ltd. | 2020-12-21 |
| A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers. (NCT04485585) | Boryung Pharmaceutical Co., Ltd | 2020-07-20 |
| Application of MOSES Technology in BPH (NCT04648176) | Hospital Universitari Vall d'Hebron Research Institute | 2020-03-06 |
| Prostatic Urethral Lift (PUL) Pre-/Post-Radiation Treatment for Prostate Cancer (NCT03817216) | Case Comprehensive Cancer Center | 2019-12-01 |
| Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) (NCT04032067) | GemVax & Kael | 2019-10-30 |
| Urodynamic Evaluation of Disobstrucitve Power of Aquablation VS Laser Techniques (NCT03846700) | University of Bari | 2019-03-01 |
| French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (NCT03191734) | PROCEPT BioRobotics | 2017-09-19 |
| Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres (NCT03052049) | Northwestern University | 2017-09-06 |
| Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II (NCT03123250) | PROCEPT BioRobotics | 2017-08-14 |
| Taiwan ACE Beads for Embolization Therapy in Symptomatic Benign Prostatic Hyperplasia (NCT03239652) | National Cheng-Kung University Hospital | 2017-01-01 |
| Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (NCT02592473) | University of Virginia | 2015-11-01 |
| Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER) (NCT02505919) | PROCEPT BioRobotics | 2015-10-30 |
| A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH (NCT02855892) | GemVax & Kael | 2015-10-01 |
| Benign Prostatic Hyperplasia and Ischemic Heart DIsease (NCT03856242) | I.M. Sechenov First Moscow State Medical University | 2015-09-01 |
| Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate (NCT03460873) | Samsung Medical Center | 2015-09-01 |
| Study to Assess the Efficacy of Medi-Tate iTind Device (NCT02145208) | Medi-Tate Ltd. | 2014-10-01 |
| PERmixon® in LUTS Evaluation Study (PERLES) (NCT02121613) | Pierre Fabre Medicament | 2014-04-01 |
| A Prospective Investigation Using the Expired Breath Ethanol Test (NCT02304549) | Daniel Stephan Engeler | 2014-04-01 |
| Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US) (NCT01896973) | HistoSonics, Inc. | 2013-07-01 |
| Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada) (NCT01775488) | HistoSonics, Inc. | 2013-06-01 |
| Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) (NCT01604811) | Pierre Fabre Medicament | 2012-06-01 |
| Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia (NCT01500057) | Brooklyn Urology Research Group | 2011-12-01 |
| A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (NCT00970632) | Eli Lilly and Company | 2009-10-01 |
| Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy (NCT01566292) | Catholic University of the Sacred Heart | 2009-09-01 |
| Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS) (NCT00939120) | Siami, Paul F., M.D. | 2009-07-01 |
| Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018 (NCT00945490) | Nymox Corporation | 2009-05-01 |
| Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH) (NCT00743184) | Spectrum Pharmaceuticals, Inc | 2008-12-04 |
| A Study to Determine the Safety and Efficacy of a New Non-invasive Heating Garment to Reduce Urinary Hesitancy (NCT00700505) | ThermaRx, Inc. | 2008-04-01 |
| A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806) (NCT00651807) | Organon and Co | 2008-03-01 |
| Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms (NCT02715024) | Astellas Pharma Taiwan, Inc. | 2007-09-01 |
| Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate) (NCT00759135) | Nymox Corporation | 2007-05-01 |
| A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo (NCT00224107) | Watson Pharmaceuticals | 2005-05-01 |
| A Comparative Study of KSO-0400 in BPH Patients With LUTS (NCT01222650) | Kissei Pharmaceutical Co., Ltd. | |